Inhibition of monocarboxylate transporter by N-cyanosulphonamide S0859
Related Experiment Video
Updated: Apr 11, 2026

Methods to Inhibit Bacterial Pyomelanin Production and Determine the Corresponding Increase in Sensitivity to Oxidative Stress
Published on: August 31, 2015
Hella Heidtmann1, Iván Ruminot1, Holger M Becker1
1Abteilung für Allgemeine Zoologie, FB Biologie, University of Kaiserslautern, P.B. 3049, D-67653 Kaiserslautern, Germany.
Abstract:
The synthetic compound N-cyanosulphonamide S0859 has been described as a selective inhibitor of sodium-bicarbonate cotransporters (NBC, SLC4) in mammalian heart (Ch'en et al., 2008). First, for comparison, the electrogenic human NBCe1 (SLC4A4) was heterologously expressed in Xenopus laevis oocytes, where its transport activity was inhibited by S0859 with an IC50 of 9µM. The activity of monocarboxylate transporter (MCT) isoforms 1, 2, and 4 (SLC16A1, SLC16A7, SLC16A3), which transport lactate, pyruvate and ketone bodies, were also heterologously expressed in Xenopus oocytes, and their transport activity was similarly and reversibly inhibited by S0859 with an IC50 of 4-10µM. Partial inhibition of lactate transport by S0859 (50µM) was also obtained in cultured astrocytes of mice. Thus, S0859 appears to be an inhibitor of anion transport with a broader spectrum than previously thought, and may also interfere with cellular metabolite uptake/release.
Related Concept Videos
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
Cholinergic Antagonists: Pharmacokinetics
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

